Advertisement

Central European Journal of Medicine

, Volume 6, Issue 2, pp 163–171 | Cite as

Natural history of Polish patients with mucopolysaccharidosis type VI

  • Agnieszka Jurecka
  • Agnieszka Rozdzynska
  • Jolanta Marucha
  • Barbara Czartoryska
  • Grzegorz Wegrzyn
  • Anna Tylki-Szymanska
Research Article

Abstract

The aim of the study was to describe the natural history, anthropometric features, range of motion (ROM) and molecular characteristics of Polish patients with mucopolysaccharidosis (MPS) VI. Clinical heterogeneity was observed and two major clinical phenotypes of the disease were distinguished, rapidly advancing and relatively attenuated. Two patients developed symptoms early in life presenting with short stature, significant skeletal malformations and other clinical abnormalities. In two other patients, height was only slightly decreased and MPS features developed later in the course of the disease. All patients had similar characteristics at the time of birth but showed significant differences in body proportions when compared with the healthy population. Differences between healthy and affected children increased with age and were reflected in phenotypes. Analysis of ROM showed impairments at multiple joints, although to a various degree in different patients. Restriction in upper extremity ROM was observed since the second year of life, while restriction in lower extremity ROM developed later and influenced stereotype of walking. These limitations intensified with the patients’ age, which made self-care more difficult or impossible. The molecular analysis revealed that the milder phenotype may be associated with the R152W mutation, which suggests a specific genotype-phenotype correlation.

Keywords

Maroteaux-Lamy syndrome Mucopolysaccharidosis type VI Anthropometric features Growth patterns Growth retardation Range of motion Physical therapy 

Abbreviations

ERT

enzyme replacement therapy

GAG

glycosaminoglycan

MPS

mucopolysaccharidosis

ROM

range of motion

SFTR

sagittal, frontal, transverse rotation system

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Neufeld EF, Muenzer J., The mucopolysaccharidoses. In Scriver CR, Beaudet AL, Sly WS, et al., (Eds.), The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001Google Scholar
  2. [2]
    Azevedo AC, Schwartz IV, Kalakun L, et al., Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI, Clin. Genet., 2007, 66, 208–213CrossRefGoogle Scholar
  3. [3]
    Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease. Dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly, Am. J. Pathol., 2000, 156, 925–938CrossRefPubMedGoogle Scholar
  4. [4]
    Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I), Curr. Opin. Rheum., 2005, 17, 70–78CrossRefGoogle Scholar
  5. [5]
    Simonaro CM, D’Angelo M, He X, et al., Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases, Am. J. Pathol., 2008, 172, 112–122CrossRefPubMedGoogle Scholar
  6. [6]
    Tylki-Szymanska A, Marucha J, Jurecka A, et al., Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted upper extremities range of motion in MPS I patients, J. Inherit. Metab. Dis., (in press), DOI 10.1007s/10545-010-9059-9Google Scholar
  7. [7]
    Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II, Acta Paediatr., (in press), DOI 10.1111/j.1651-2227.2010.02060.xGoogle Scholar
  8. [8]
    Sifuentes M, Doroshow R, Hoft R, et al., A followup study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years, Mol. Genet. Metab., 2007, 90, 171–180CrossRefPubMedGoogle Scholar
  9. [9]
    Cardoso-Santos A, Azevedo AC, Fagondes S, et al., Mucopolisaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength, J. Pediatr. (Rio J), 2008, 84, 130–135CrossRefGoogle Scholar
  10. [10]
    Tylki-Szymanska A, Rozdzynska A, Jurecka A, et al., Anthropometric data of 14 patients with mucopolysaccharidosis I: restrospective analysis and efficacy of recombinant human alpha-Liduronidase (laronidase), Mol. Genet. Metab., 2010, 99, 10–17CrossRefPubMedGoogle Scholar
  11. [11]
    Harmatz P, Giugliani R, Schwartz I, et al., Enzyme replacement therapy formucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study, J. Pediatr., 2006, 148, 533–539CrossRefPubMedGoogle Scholar
  12. [12]
    Scarpa M, Barone R, Fiumara A, et al., Mucopolysaccharidosis VI: the Italian experience, Eur. J. Pediatr., 2009, 168, 1203–1206CrossRefPubMedGoogle Scholar
  13. [13]
    McGill JJ, Inwood AC, Coman DJ, et al., Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age — a sibling control study, Clin. Genet., 2010, 77, 492–498CrossRefPubMedGoogle Scholar
  14. [14]
    Gerhardt JJ, Clinical measurements of joint motion and position in the neutral-zero method and SFTR recording: Basic principles, Disability & Rehabilitation, Volume 5, Issue 4, 1983Google Scholar
  15. [15]
    Gerhardt JJ, Rondinelli RD. Goniometric techniques for range-of-motion assessment, P h y s. Med. Rehabil. Clin. N. Am., 2001, 12, 507–527Google Scholar
  16. [16]
    Zembaty A, Kinezyterapia, volume 1; Krakow, 2002Google Scholar
  17. [17]
    Pennock CA. A modified screening test for glycosaminoglycan excretion, J. Clin. Pathol., 1969, 22, 379–380CrossRefPubMedGoogle Scholar
  18. [18]
    Humbel R. Rapid method for measuring arylsulfatase A and B in leucocytes as a diagnosis for sulfatidosis, mucosulfatidosis and mucopolysaccharidosis VI, Clin. Chim. Acta, 1976, 68, 339–361CrossRefPubMedGoogle Scholar
  19. [19]
    Dubois G, Turpin JC, Bauman N., Utilisation de l’électrophorese pour la détection de la Leucodystrophie Metachromatique á partir de leucocytes humains. C.R.Acad.Sc.Paris 278, Serie D, 1974Google Scholar
  20. [20]
    Palczewska I, Niedźwiedzka Z., Wskaźniki rozwoju somatycznego dzieci i mŁodzieży warszawskiej, Medycyna Wieku Rozwojowego V. Suplement I do nr 2, 2001Google Scholar
  21. [21]
    Cieslik J, Kaczmarek M, Kaliszewska-Drozdowska MD., Dziecko Poznanskie’ 90. Wzrastanie, dojrzewanie, normy i metody rozwoju. (The Poznan Child’90. Growth, Development, Reference standards.). Poznan: Wydawnictwo Naukowe Bogucki, 1994Google Scholar
  22. [22]
    Voskoboeva E, Isbrandt D, von Figura K, et al., Four novel mutatnt alleles of the arylosulfatase B gene in two patients with intermediate form of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome), Hum. Genet., 1994, 93, 259–264CrossRefPubMedGoogle Scholar
  23. [23]
    Karageorgos L, Brooks DA, Pollard A, et al., Mutational analysis of 105 mucopolysaccharidosis type VI patients, Hum. Mutat., 2007, 28, 897–903CrossRefPubMedGoogle Scholar
  24. [24]
    Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymanska A, et al., Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and defficiency of glycosaminoglycan synthesis, Acta Paediatr., 2009, 98, 743–749CrossRefPubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Agnieszka Jurecka
    • 1
    • 4
  • Agnieszka Rozdzynska
    • 2
  • Jolanta Marucha
    • 1
  • Barbara Czartoryska
    • 3
  • Grzegorz Wegrzyn
    • 4
  • Anna Tylki-Szymanska
    • 1
  1. 1.Department of Metabolic Diseases, Endocrinology and DiabetologyThe Children’s Memorial Health InstituteWarsawPoland
  2. 2.Anthropometry LaboratoryThe Children’s Memorial Health InstituteWarsawPoland
  3. 3.Department of GeneticsInstitute of Psychiatry and NeurologyWarsawPoland
  4. 4.Department of Molecular BiologyUniversity of GdanskGdanskPoland

Personalised recommendations